Physician profile
Michael E Cohen
NPI 1841281912
$7,597.18
in general payments reported to CMS, 2019-2025
24 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,483 · 2020: $451 · 2021: $614 · 2022: $520 · 2023: $578 · 2024: $687 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,483.65 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Microaire Surgical Instruments LLC | $1,971.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $474.12 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $327.14 | 2019-2025 | Tremfya |
| Celgene Corporation | $286.22 | 2021-2024 | Zeposia |
| Inari Medical, INC. | $192.02 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Gilead Sciences, INC. | $133.61 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $111.58 | 2021-2023 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $97.49 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.50 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $61.82 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $56.85 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $47.62 | 2023 | Advanix Biliary, Exalt Model D |
| Redhill Biopharma INC. | $46.23 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $40.69 | 2019-2023 | Dificid, Zinplava |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $33.16 | 2019 | |
| Intercept Pharmaceuticals, INC. | $30.53 | 2019-2022 | |
| Genzyme Corporation | $25.94 | 2024 | |
| Amgen INC. | $25.29 | 2025 | Uplizna |
| Allergan, INC. | $25.02 | 2019-2020 | |
| Axonics, INC. | $18.56 | 2023 | Axonics |
| Ardelyx, INC. | $15.45 | 2023 | Ibsrela |
| Alfasigma USA, INC. | $12.29 | 2020 | |
| Ucb, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.